CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
Through this initiative, CVS Health is launching a new tool called the CVS Pharmacy Rx Savings Finder. The tool will allow the company’s retail pharmacists to quickly evaluate individual prescription savings opportunities at the pharmacy counter for the first time.
The tool will show pharmacy teams whether the prescribed medication is on the patient’s formulary and if it’s the most affordable available option. Using the Rx Savings Finder, the pharmacist will also be able to identify whether the patient might be able to save money by filling a 90-day prescription rather than a 30-day prescription.
“Armed with the information available through our Rx Savings Finder, our more than 30,000 CVS pharmacists can play an important role by helping patients save money on their medications, providing advice on how and when to take them, and ultimately helping them achieve better health outcomes,” said Kevin Hourican, executive vice president of retail pharmacy at CVS Pharmacy. “We are beginning this process with our CVS Caremark [pharmacy benefit manager, PBM] members and expect to roll it out more broadly throughout the year.”
In another effort to combat high drug prices, the company’s PBM, CVS Caremark, is also offering its members preventive drug lists that itemize medications for many common chronic conditions that are available with no co-pay. CVS Caremark also provides a real-time benefits program with which, at time of prescribing, providers are able to see member-specific drug costs based on formulary, along with up to 5 of the lowest-cost, clinically appropriate alternatives.
During a pilot program, CVS found that 95% of patients asked to switch drugs to a lower-cost option when given the choice, and 85% of doctors also chose to make such a switch.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.